Quantbot Technologies LP Takes Position in Enfusion, Inc. (NYSE:ENFN)

Quantbot Technologies LP bought a new position in shares of Enfusion, Inc. (NYSE:ENFN) during the 4th quarter, HoldingsChannel reports. The firm bought 13,950 shares of the company’s stock, valued at approximately $144,000.

Several other hedge funds also recently added to or reduced their stakes in ENFN. Intech Investment Management LLC acquired a new stake in Enfusion in the fourth quarter worth about $191,000. Royce & Associates LP grew its position in Enfusion by 84.6% during the 4th quarter. Royce & Associates LP now owns 184,078 shares of the company’s stock worth $1,896,000 after purchasing an additional 84,363 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in Enfusion by 1.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 371,151 shares of the company’s stock valued at $3,823,000 after purchasing an additional 5,639 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Enfusion by 3.3% in the fourth quarter. Bank of New York Mellon Corp now owns 126,541 shares of the company’s stock worth $1,303,000 after buying an additional 4,032 shares during the last quarter. Finally, Impax Asset Management Group plc lifted its stake in shares of Enfusion by 31.5% during the fourth quarter. Impax Asset Management Group plc now owns 890,000 shares of the company’s stock worth $9,167,000 after buying an additional 213,052 shares during the period. 81.05% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently issued reports on ENFN. William Blair reissued a “market perform” rating on shares of Enfusion in a research report on Monday, January 13th. Stifel Nicolaus raised their price objective on Enfusion from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, December 18th. Finally, Piper Sandler upped their target price on Enfusion from $10.00 to $11.50 and gave the company a “neutral” rating in a research report on Monday, December 23rd.

Enfusion Stock Performance

Shares of ENFN opened at $11.11 on Monday. The business’s 50-day moving average is $11.18 and its two-hundred day moving average is $10.21. The company has a market capitalization of $1.43 billion, a P/E ratio of 277.69, a P/E/G ratio of 1.85 and a beta of 0.95. Enfusion, Inc. has a fifty-two week low of $7.83 and a fifty-two week high of $11.80.

Enfusion (NYSE:ENFN) last announced its quarterly earnings results on Monday, March 3rd. The company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.02). Enfusion had a net margin of 1.70% and a return on equity of 6.67%. The company had revenue of $52.94 million for the quarter, compared to analysts’ expectations of $53.98 million. Analysts forecast that Enfusion, Inc. will post 0.06 EPS for the current year.

Insider Activity

In other news, CEO Oleg Movchan sold 2,771 shares of the stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $10.13, for a total transaction of $28,070.23. Following the transaction, the chief executive officer now owns 526,702 shares in the company, valued at $5,335,491.26. This trade represents a 0.52 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Neal Pawar sold 2,769 shares of the business’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $11.48, for a total transaction of $31,788.12. Following the completion of the sale, the chief operating officer now directly owns 1,231,627 shares of the company’s stock, valued at approximately $14,139,077.96. The trade was a 0.22 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 77,346 shares of company stock valued at $868,109 in the last three months. 36.44% of the stock is currently owned by corporate insiders.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.